On Friday, Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was -3.23% drop from the session before settling in for the closing price of $4.95. A 52-week range for GLUE has been $3.50 – $12.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -41.09% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 55.39%. With a float of $45.99 million, this company’s outstanding shares have now reached $61.51 million.
In an organization with 134 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.42%, operating margin of -1.33%, and the pretax margin is 5.93%.
Monte Rosa Therapeutics Inc (GLUE) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Monte Rosa Therapeutics Inc stocks. The insider ownership of Monte Rosa Therapeutics Inc is 25.23%, while institutional ownership is 79.32%. The most recent insider transaction that took place on Jun 03 ’25, was worth 9,174. In this transaction Principal Accounting Officer of this company sold 2,062 shares at a rate of $4.45, taking the stock ownership to the 23,732 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Director bought 10,000 for $5.84, making the entire transaction worth $58,383. This insider now owns 10,000 shares in total.
Monte Rosa Therapeutics Inc (GLUE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 55.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.54% during the next five years compared to -41.09% drop over the previous five years of trading.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Trading Performance Indicators
You can see what Monte Rosa Therapeutics Inc (GLUE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.85. Likewise, its price to free cash flow for the trailing twelve months is 9.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.07, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.44 in one year’s time.
Technical Analysis of Monte Rosa Therapeutics Inc (GLUE)
Let’s dig in a bit further. During the last 5-days, its volume was 0.53 million. That was inferior than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 15.05%.
During the past 100 days, Monte Rosa Therapeutics Inc’s (GLUE) raw stochastic average was set at 33.86%, which indicates a significant increase from 0.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.38 in the past 14 days, which was higher than the 0.36 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.92, while its 200-day Moving Average is $6.01. However, in the short run, Monte Rosa Therapeutics Inc’s stock first resistance to watch stands at $4.91. Second resistance stands at $5.04. The third major resistance level sits at $5.10. If the price goes on to break the first support level at $4.72, it is likely to go to the next support level at $4.66. The third support level lies at $4.53 if the price breaches the second support level.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Key Stats
There are 61,510K outstanding shares of the company, which has a market capitalization of 294.63 million. As of now, sales total 75,620 K while income totals -72,700 K. Its latest quarter income was 84,930 K while its last quarter net income were 46,890 K.
